EPO and myeloproliferative disorder: The JAK2 V617F mutation, which is associated with myeloproliferative disorders and EPO hypersensitivity [38], was identified exclusively in blasts of TgSpi1FA+/+ mice, including #445 and #451, with VAF values of 28 and 18%, respectively.